Tag Archive for Kite Pharma

| October 21, 2017
No comments

FDA approves Israeli-developed, personally tailored cancer-killer drug

Developed by researchers at Israel’s Weizmann Institute and Sourasky Medical Center, the U.S. Food and Drug Administration fast-tracked the approval for their cancer treatment Yescarta, based on technology that uses the patient’s immune system to destroy cancer cells.
• List price in U.S. for the personally tailored drug is $373,000.

By Hezi Sternlicht & Israel Hayom Staff

 

Kite Pharma, founded by Israeli-American Professor Arie Belldegrun in 2009, has announced that the U.S. Food and Drug Administration has granted regular approval for its cancer treatment Yescarta.

California-based Gilead Sciences bought Kite Pharma for $12 billion in August this year.

Professor Arie Belldegrun – Photo: Kite Pharma

The product, which was approved on a fast-track process, is based on innovative technology that recruits the body’s immune system to identify and destroy cancer cells. Continue Reading »

Category: Innovations & Discoveries, Israel News | Tags: , , , , ,
| August 29, 2017
No comments

US pharmaceutical giant acquires Israeli biomed firm for $12 billion

U.S. biopharmaceutical firm announced its decision to pay $11.9 billion for Kite Pharma, an Israeli biomed developing T-cell therapy that harnesses the body’s immune cells to attack malignant cells.
• This pharmaceutical acquisition is among the most spent for a company whose products have yet to be FDA approved.

By Zeev Klein, News Agencies & Israel Hayom Staff

 

Biopharmaceutical giant Gilead Sciences announced Monday that it has agreed to buy Israeli biomed company Kite Pharma for $11.9 billion in an all-cash deal. This acquisition marks one of the biggest ever deals for a company whose products have yet to be approved for marketing. Continue Reading »

Category: Israel News | Tags: , , ,